VBIV - VBI Vaccines Inc.
| Previous Close | 3.31 |
| Open | 3.27 |
| Bid | 3.18 x 600 |
| Ask | 3.20 x 300 |
| Day's Range | 3.11 - 3.35 |
| 52 Week Range | 3.04 - 5.10 |
| Volume | 116,097 |
| Avg. Volume | 117,029 |
| Market Cap | 204.206M |
| Beta | 1.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.88 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.30 |
- GlobeNewswire•yesterday
VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
The PROTECT study is one of two ongoing global studies that form the Phase 3 program for Sci-B-Vac®. It is designed to evaluate the safety and immunogenicity of Sci-B-Vac® compared with the control vaccine, Engerix-B®, in support of future regulatory filings in the U.S., Europe, and Canada. Sci-B-Vac is currently approved for use in Israel and in 14 other countries.
- GlobeNewswire•3 days ago
VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
Independent Data and Safety Monitoring Board unanimously recommends continuation of study without modification Low-dose study arm: enrollment complete Intermediate-dose study arm: enrollment commenced. ...
- Benzinga•last month
ICYMI: Penny Stocks, Energy ETF, AR And VR Devices
In case you missed it, here are some of Benzinga's top stories from Thursday, March 15th, 2018. Energy Stocks And ETFs Struggle For energy investors, the weakness in energy stocks and ETFs that characterized ...
- GlobeNewswire•last month
VBI Vaccines Announces Voluntary Delisting from the Toronto Stock Exchange
CAMBRIDGE, Mass., March 12, 2018-- VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has ...
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for Progress Software, Cracker Barrel Old Country Store, Natural Grocers by Vitamin Cottage, VBI Vaccines, Ardelyx, and CytomX Therapeutics — Fundamental Analysis, Key Performance Indications
NEW YORK, Feb. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Progress ...
- GlobeNewswire•3 months ago
VBI Vaccines Announces Changes to its Board of Directors
Sam Chawla, of Perceptive Advisors, to resign from VBI Board of Directors Tomer Kariv, Chairman and CEO of The Pontifax Group, to replace Ran Nussbaum on VBI’ s Board of Directors. CAMBRIDGE, Mass., Jan. ...
- Capital Cube•4 months ago
ETFs with exposure to VBI Vaccines, Inc. : December 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VBI Vaccines, Inc. Here are 5 ETFs with the largest exposure to VBIV-US. Comparing the performance and risk of VBI Vaccines, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube•4 months agoVBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
Categories: Yahoo FinanceGet free summary analysis VBI Vaccines, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of VBI Vaccines, Inc. – Pieris Pharmaceuticals, Inc. and PDL BioPharma, Inc. (PIRS-US and PDLI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.19 ... Read more (Read more...)
- Benzinga•5 months ago
VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO
VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV ) will release results on three clinical trials in the first half of 2018, presenting certain investment opportunities of an uncertain nature. Some on ...
- Zacks Small Cap Research•5 months ago
VBI: Multiple Platforms Yield a Portfolio of Vaccines
NASDAQ:VBIV VBI Vaccines, Inc. (NASDAQ:VBIV) is a Cambridge, Massachusetts-based biopharmaceutical company developing a portfolio of vaccines including solutions for hepatitis B, cytomegalovirus (CMV) ...
- Marketwired•6 months ago
VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017
VBI Vaccines Inc. today announced the company's abstract, "Antibody and Cell-mediated Immunity against PreS1, PreS2, and S Antigens after Immunizations with a Third Generation Hepatitis B Vaccine," ...
- Marketwired•6 months ago
VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona
VBI Vaccines Inc. today announced that Adam Buckley, vice president of business development, will discuss VBI's enveloped virus-like particle platform, highlighting data from two of the company's vaccine ...
- Marketwired•7 months ago
VBI Vaccines to Present at September 2017 Investor Conferences
VBI Vaccines Inc. today announced that Jeff Baxter, President and CEO, will provide a corporate overview and update at two investor conferences in September.
- Marketwired•8 months ago
VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program
VBI Vaccines Inc. (VBIV)(VBV.TO) (VBI) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug Application (IND) for a Phase 3 clinical program evaluating Sci-B-Vac®, VBI's third-generation hepatitis B vaccine. The company had previously received a No Objection Letter (NOL) from Health Canada in response to its Clinical Trial Application (CTA) as well.
- Capital Cube•8 months ago
ETFs with exposure to VBI Vaccines, Inc. : August 28, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VBI Vaccines, Inc. Here are 5 ETFs with the largest exposure to VBIV-US. Comparing the performance and risk of VBI Vaccines, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Marketwired•8 months ago
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
VBI Vaccines Inc. today announced that David Anderson, Ph.D., Chief Scientific Officer of VBI, will present new preclinical data demonstrating the mechanism by which VBI-1901 stimulates CMV-specific immunity ...